Alphamab Oncology announced that Mr. XU Zhan Kevin ("Mr. Xu") has tendered his resignation from the position as a non-executive Director with effect from June 30, 2023 due to his other work commitments. Following his resignation as a non-executive Director, Mr. Xu has ceased to be a member of the strategy committee of the Company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.99 HKD | +3.82% | +17.72% | -54.97% |
05/06 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
05/06 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.97% | 37Cr | |
+55.55% | 5.93TCr | |
+43.17% | 4.02TCr | |
-4.71% | 3.99TCr | |
-5.56% | 2.86TCr | |
+13.76% | 2.73TCr | |
-22.00% | 1.92TCr | |
+31.50% | 1.26TCr | |
+2.16% | 1.25TCr | |
+25.70% | 1.23TCr |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee